



A Novel Mutation of INSR Gene in a Child with Type A Insulin Resistance

Federica Verdecchia¹, Neşe Akcan¹, Antonia Dastamani¹, Kate Morgan¹, Robert Semple³, Pratik Shah^{1,2}

- 1. Endocrinology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK
- 2. Genetics and Epigenetics in Health and Disease Section, Genetics and Genomics Medicine Program, UCL GOS Institute of Child Health, London, UK
- 3. Chair of Translational Molecular Medicine, Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK

Background Output Actions of insulin receptor gene (INSR) lead to a wide spectrum of inherited insulin resistance syndromes. Type A insulin resistance is one of the these syndromes which is inherited autosomal dominant and leads to mild clinical symptoms after puberty (1).

Objective

P3-266

U To report a novel mutation of INSR gene mutation in a case of Type A insulin resistance who presented with transient neonatal diabetes and then episodes of hypoglycaemia and hyperglycaemia during childhood.

Case:

- **U** Full-term Afro-Caribbean female infant, of birth weight 1.89 kg, developed transient neonatal diabetes with negative genetic testing (microarray, **TNDM 6q methylation analysis).**
- At the age of 2.8 years, she presented with episodes of postprandial and fasting hypoglycaemia. Her examination showed satisfactory growth, lipodystrophy, acanthosis nigricans and isolated thelarche.
- Investigations demonstrated that the child after 12 hours of fasting developed hypoglycaemia (glucose 2.8 mmol/L), with inappropriately raised insulin level of 5.4 mU/L.
- □ Her oral glucose tolerance test (OGTT) (Table 1) showed excessively high levels of insulin throughout the test (>300 mU/L) along with hypoglycaemia (glucose 1.6 mmol/L) at 2.5 hours of the test. She had dietary modification with some improvement in hypoglycaemia. **U** She continued to have postprandial hypoglycaemia and was started on Acarbose 12.5mg TDS (upto 25mg TDS) at the age of 5 years. □ She had negative genetic analysis for Familial Lipodystrophy (LMNA and PPARG genes) and Hyperinsulinism (ABCC8 and KCNJ11 genes). □ She was stabilized on acarbose treatment (upto 25mg TDS) for the management of PPHH that lasted for 2.5 years.
- **U** Subsequently, she developed intermittent episodes of hyperglycaemia along with postprandial and fasting episodes of hypoglycaemia recorded persistently on continuous glucose monitoring.
- □ HbA1c and fasting lipids remained within the normal range.
- **U** Suppressed and rogens and pelvic ultrasound with pre-pubertal appearance of her internal genitalia until the age of 8.7 years.

□ Normal baseline pituitary function.

LHRH showed predominant FSH response.

- Treatment of metformin along with carbohydrate diet modification and corn starch started at the age of 7 years not only improved fasting tolerance but also episodes of hyperglycaemia and post-prandial hypoglycaemia.
- Genetic testing identified a novel heterozygous deletion of exon 22 in INSR gene.

Table 1: Oral Glucose Tolerance test (OGTT)

Age: 4 years

Age: 2 years and 8 months

Time (Min)	0	30	60	90	120	150
Blood glucose (mmol/L)	3.7	9.2	11.9	6.5	5.7	1.6
Insulin (mU/L)	19.9	>300	>300	>300	>300	225

Time (Min) 60 0 30 90 120 150 3.2 6.1 4.3 **Blood glucose** 8.4 6.4 2.4 (mmol/L) 7.5 >300 240 127 Insulin (mU/L) >300 >300

Conclusion:

U The present case details the clinical features of a patient with genetically proven Type A insulin resistance.

- □ The major features of this condition usually becoming clinically apparent in adolescence (2).
- **U** Early age manifestation, neonatal diabetes and also PPHH can be another presentation of this disease.
- The remarkable point of the current case report is early different clinical presentation of Type A-IR with a novel INSR mutation that illustrates a range of different glycaemic presentations, and how IR can masquerade as other disorders.
- □ Children with this can be quite challenging to manage using pharmacotherapy and dietary modification (3).
- **U** Further accumulation of genetically proven cases and long-term treatment outcomes following early diagnosis are required to understand the dynamics of this disease.

References

- 1. Semple RK, Savage DB, Brierley GV, O'Rahilly S Syndromes of Severe Insulin Resistance and/or Lipodystrophy, chapter in Genetic Diagnosis of Endocrine Disorders 2nd Ed (2015, Elsevier, eds Weiss and Refetoff).
- Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocr Rev. 2011;32(4):498-514-0. 2.
- 3. Parker V.E.R, Semple R.K. Genetic Forms of Severe Insulin Resistance: What Endocrinologists Should Know. Eur J Endocrinol. 2013 Oct; 169(4): R71–R80.



